Published OnlineFirst May 21, 2015; DOI: 10.1158/1535-7163.MCT-15-0297
Correction
Correction: Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors
Molecular Cancer Therapeutics
In this article (Mol Cancer Ther 2014;13:2141–8), published in the September 2014 issue of Molecular Cancer Therapeutics (1), Figure 2 and Supplementary Figure 1 remained from an unrevised version of the manuscript and present incorrect structures for compounds BMS777607, MGCD265, SGI7079 and S49076. The correct structures of these compounds are presented below in Figure 2 and Supplementary Figure 1. The authors apologize for the errors.
A
N
B
N
O N
HN N
H N
O
O
O O
H N
N
SGI7079 Tolero Pharmaceucals
N
O N O
O
H N
Cl
Cl
CN
Bond
Hydrogen bond acceptor substuted phenyl group
O
F
F
Cl N
H N
N
Bosunib, Bosulif® Pfizer
N O
N
N
Hinge bonding heterocycle with a solubilizing group
H N
H2N
O
MGCD265 Mira Therapeucs
O
F
N
N
N H
N H
Forenib Exeliris, GlaxoSmithKline
H N S
O S
N
F
F
CN
N
O
O
O N
O
Cabozannib, Cometriq® Exeliris
H N
H N
N
O
N
N
F
O
TP0903 Tolero Pharmaceucals
N
HN
O
O
O
S N
Cl
F
H N
H N
N
N O
O
O
F
F
Hinge bonding Oxygen bond heterocycle with or (o-fluoro) without a phenyl solubilizing group group
BMS777607 Aslan Pharmaceucals, Bristol-Myers Squibb
Hydrogen donor and acceptor sequence
LY2801653 Eli Lilly Company
(p-fluoro) phenyl group
Figure 2.
Reference 1. Feneyrolles C, Spenlinhauer A, Guiet L, Fauvel B, Dayde-Cazals B, Warnault P, et al. Axl kinase as a key target for oncology: focus on small molecule inhibitors. Mol Cancer Ther 2014;13:2141–8. Published OnlineFirst May 21, 2015. doi: 10.1158/1535-7163.MCT-15-0297 Ó2015 American Association for Cancer Research.
1518
Mol Cancer Ther; 14(6) June 2015
Downloaded from mct.aacrjournals.org on November 18, 2015. © 2015 American Association for Cancer Research.
Published OnlineFirst May 21, 2015; DOI: 10.1158/1535-7163.MCT-15-0297
Correction: Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors Mol Cancer Ther 2015;14:1518. Published OnlineFirst May 21, 2015.
Updated version Supplementary Material
Cited articles
E-mail alerts Reprints and Subscriptions Permissions
Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-15-0297 Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2015/05/21/1535-7163.MCT-15-0297.DC1.html
This article cites 1 articles, 1 of which you can access for free at: http://mct.aacrjournals.org/content/14/6/1518.full.html#ref-list-1
Sign up to receive free email-alerts related to this article or journal. To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [email protected]. To request permission to re-use all or part of this article, contact the AACR Publications Department at [email protected].
Downloaded from mct.aacrjournals.org on November 18, 2015. © 2015 American Association for Cancer Research.
Correction
Correction: Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors
Molecular Cancer Therapeutics
In this article (Mol Cancer Ther 2014;13:2141–8), published in the September 2014 issue of Molecular Cancer Therapeutics (1), Figure 2 and Supplementary Figure 1 remained from an unrevised version of the manuscript and present incorrect structures for compounds BMS777607, MGCD265, SGI7079 and S49076. The correct structures of these compounds are presented below in Figure 2 and Supplementary Figure 1. The authors apologize for the errors.
A
N
B
N
O N
HN N
H N
O
O
O O
H N
N
SGI7079 Tolero Pharmaceucals
N
O N O
O
H N
Cl
Cl
CN
Bond
Hydrogen bond acceptor substuted phenyl group
O
F
F
Cl N
H N
N
Bosunib, Bosulif® Pfizer
N O
N
N
Hinge bonding heterocycle with a solubilizing group
H N
H2N
O
MGCD265 Mira Therapeucs
O
F
N
N
N H
N H
Forenib Exeliris, GlaxoSmithKline
H N S
O S
N
F
F
CN
N
O
O
O N
O
Cabozannib, Cometriq® Exeliris
H N
H N
N
O
N
N
F
O
TP0903 Tolero Pharmaceucals
N
HN
O
O
O
S N
Cl
F
H N
H N
N
N O
O
O
F
F
Hinge bonding Oxygen bond heterocycle with or (o-fluoro) without a phenyl solubilizing group group
BMS777607 Aslan Pharmaceucals, Bristol-Myers Squibb
Hydrogen donor and acceptor sequence
LY2801653 Eli Lilly Company
(p-fluoro) phenyl group
Figure 2.
Reference 1. Feneyrolles C, Spenlinhauer A, Guiet L, Fauvel B, Dayde-Cazals B, Warnault P, et al. Axl kinase as a key target for oncology: focus on small molecule inhibitors. Mol Cancer Ther 2014;13:2141–8. Published OnlineFirst May 21, 2015. doi: 10.1158/1535-7163.MCT-15-0297 Ó2015 American Association for Cancer Research.
1518
Mol Cancer Ther; 14(6) June 2015
Downloaded from mct.aacrjournals.org on November 18, 2015. © 2015 American Association for Cancer Research.
Published OnlineFirst May 21, 2015; DOI: 10.1158/1535-7163.MCT-15-0297
Correction: Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors Mol Cancer Ther 2015;14:1518. Published OnlineFirst May 21, 2015.
Updated version Supplementary Material
Cited articles
E-mail alerts Reprints and Subscriptions Permissions
Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-15-0297 Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2015/05/21/1535-7163.MCT-15-0297.DC1.html
This article cites 1 articles, 1 of which you can access for free at: http://mct.aacrjournals.org/content/14/6/1518.full.html#ref-list-1
Sign up to receive free email-alerts related to this article or journal. To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [email protected]. To request permission to re-use all or part of this article, contact the AACR Publications Department at [email protected].
Downloaded from mct.aacrjournals.org on November 18, 2015. © 2015 American Association for Cancer Research.
